Lung Cancers | Oncology Updates

Dedicated to Lung Cancer, providing expert insights into the latest therapeutic advancements and innovations in treatment strategies

About Event

The 1st Oncology Updates, 8th July 2023, centered on the latest breakthroughs in Breast and Lung Cancer treatments. Expert speakers shared insights on innovative therapies, clinical strategies, and emerging research shaping the future of cancer care.

Meetings : Series 1
Track : Lung Cancers
Type : Virtual Mode
Time : 5 PM to 9 PM IST
Organizing Secretary
Dr.Ghanashyam Biswas,
Medical Oncologist

Key Intakes

8 +
Duration
62
Faculty
600 +
Delegates
24
Sessions

Event Videos

5:00 PM-5:05 PM (5 Mins)

Introduction and Context Setting for the webinar

Dr. Ghanashyam Biswas (MO)
5:05 PM-5:10 PM (5 Mins)

Quiz Breast Cancer

Dr. Soumya Surath Panda (MO)
5:10 PM-5:25 PM (15 Mins)

ASCO Updates in Breast Cancer

Dr.Vikas Talreja (MO)
5:25 PM-5:40 PM (15 Mins)

Adjuvant CDK4/6 inhibitor in breast Cancer is a standard of care

Dr Prabhaja N Mohapatra (MO)
5:40 PM-5:55 PM (15 Mins)

Neo adjuvant and Adjuvant chemotherapy in TNBC –Recent Advances

Dr. Uma Dhangi (MO)
5:55 PM-6:15 PM (20 Mins)

Oncoprecise Risk Predictor ( Prosigna)

Dr. Devavrat Arya (MO)
6:15 PM-6:30 PM (15 Mins)

HER2 Low stands tall among all subsets (Sponsored Talk-Astrazeneca)

Dr Anil Tarigopula (PATH)
6:30 PM-6:55 PM (25 Mins)

Nuances in management of DCIS

Dr. Neha Choudhary(SO)
6:55 PM-7:05PM (10 Mins)

Hereditary Breast and Ovarian Cancer

Dr. Richi Khandelwal(Gynaec ONCO)
7:05 PM-7:15 PM (10 Mins)

Evolving landscape of CDK4/6i: Implications for Clinical Practice (For HR+/HER2- mBC Patients)

Dr Sashanka Shekhar Das (MO)
7:15 PM-7:30 PM (15 Mins)

Emerging Landscape of HER2 Low: A Novel Entity in clinical practice

Dr. Ghanashyam Biswas (MO)
7:30 PM7:45 PM (15 Mins)

ASCO Updates in Lung cancer

Dr. Chetan Deshmukh (MO)
7:45 PM8:10 PM (25 Mins)

Neo Adjuvant IO and Adjuvant IO therapy in Early lung cancer

Dr. Prasad Narayanan(MO)
8:10 PM8:25 PM (15 Mins)

Adjuvant Osimertinib in Resected Lung Cancer – Fair or Unfair

Dr. Naresh Somani (MO)
8:25 PM8:40 PM (15 Mins)

Management of mNSCLC and Role of Tecentriq

Dr. Sourav Kumar Mishra (MO)
8:40 PM9:00 PM (20 Mins)

Spotlighting Non-EGFR mutated NSCLC’s (Non-small cell Lung carcinoma)

Dr. Richa Nathani (Path)
9:00 PM–9:05 PM (5 Mins)

Quiz Lung Cancer

Dr. Ghanashyam Biswas (MO)
9:05 PM– 9:10PM

Vote of thanks

Dr. Soumya Surath Panda (MO)
For More Details View Agenda

About Event

The 3rd Oncology Updates, 30th March 2024, centered on Lung Cancer, providing expert insights into recent therapeutic advancements. Discussions also highlighted innovative early detection methods and promising clinical trials shaping the future of Lung Cancer care.

Meetings : Series 3
Track : Lung Cancers
Type : Virtual Mode
Time : 05:00 PM to 9:00 PM IST
Organizing Secretary
Dr. Soumya Surath Panda,
Medical Oncology

Key Intakes

8 +
Duration
65
Faculty
1000 +
Delegates
23
Sessions

Event Videos

5:00 PM-5:05 PM (5 Mins)

Introduction and Context Setting for the webinar

Dr. Soumya Surath Panda(MO)
5:05 PM-5:10 PM (5 Mins)

Quiz-1 Lung Cancer

Dr Satya Sadhan Sarangi(MO)
5:10 PM-5:25 PM (15 Mins)

Pacific trial updates

Dr. Suresh Babu (MO)
5:25 PM-5:40 PM (15 Mins)

EBUS in Mediastinal nodal staging in NSCLC

Dr. Prashant R Mohapatra(PULM)
5:40 PM-6:10 PM (30 Mins)

Extensive stage SCLC Management

Dr.Indranil Ghosh(MO)
6:10 PM-6:25 PM (15 Mins)

Role of IO in early NSCLC

Dr.Satish CT (MO)
6:25 PM-6:40 PM (15 Mins)

Sequencing of ALK inhibitors in metastatic NSCLC

Dr. Lalatendu Maharana (MO)
6:40 PM-6:55 PM (15 Mins)

NGS in Lung Cancer Liquid Bx is acceptable

Dr. Padmaj S. Kulkarni(MO)
6:55 PM-7:25PM (30 Mins)

Immunotherapy in advanced NSCLC-how to choose?

Dr.Chetan Deshmukh(MO)
7:25 PM-7:40 PM (15 Mins)

Advanced EGFRm NSCLC- a evidence based review of Targeted therapies (IN-13394)

Dr.Ghanashyam Biswas (MO)
7:40 PM-7:55 PM (15 Mins)

Management of MET driven advanced NSCLC

Dr. Prasant Ku Parida (MO)
7:55 PM-8:25 PM (30 Mins)

Management of Lung cancer in the era of Neo-adjuvant Immuno-chemotherapy: A surgical perspective.”

Mr. Ashok Kar(SO)
8:25 PM-8:40 PM (15 Mins)

PICCing the right VAD in Oncology

Dr. Sourav Kumar Mishra(MO)
8:40 PM-8:55 PM (15 Mins)

Adjuvant Osimertinib in post op EGFR positive NSCLC

Dr. Bivas Biswas (MO)
8:55 PM-9:00 PM (5 Mins)

Lung Cancer

Dr.Sachin Sekhar Biswal(MO)
9:00 PM-9:05 PM (5 Mins)

Vote of Thanks

Dr. Tathagat Das(RO)
For More Details View Agenda